GlassScriptPhysician profile
Robert W Anderson
NPI 1790851509
$10,808.73
in general payments reported to CMS, 2019-2025
39 companies · $835 in 2025
The $835 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,651 · 2020: $1,594 · 2021: $2,002 · 2022: $1,952 · 2023: $1,554 · 2024: $1,221 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,567 · Education: $43.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,566.82 |
| Education | $43.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,506.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,200.82 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $971.99 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $940.56 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $618.53 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $605.53 | 2021-2025 | |
| Glaxosmithkline, LLC. | $580.64 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $444.30 | 2019-2024 | |
| Amgen INC. | $442.57 | 2019-2025 | Evenity, Repatha, Otezla |
| Pfizer INC. | $378.78 | 2019-2025 | |
| Allergan, INC. | $349.69 | 2019-2020 | |
| Astellas Pharma US INC | $336.61 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.20 | 2019-2025 | Jardiance, Ofev |
| Amarin Pharma, INC. | $305.58 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $304.50 | 2019-2024 | Eliquis |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.